EUVIMEDEUVIMED entdecken
Crossref

Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure

C K Zigler iD, L Lin, K Ardalan, H Jacobe, S Lane, S C Li, N J C Luca, V H Prajapati, K Schollaert, N Teske, K Torok

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von C K Zigler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Quality of Life, Scleroderma, Localized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Localized Scleroderma Quality of Life Instrument (LoSQI) is a disease‐specific patient‐reported outcome (PRO) measure designed for children and adolescents with localized scleroderma (LS; morphea). This tool was developed using rigorous PRO methods and previously cognitively tested in a sample of paediatric patients with LS.

Objective

The purpose of this study was to evaluate the psychometric properties of the LoSQI in a clinical setting.

Methods

Cross‐sectional data from four specialized clinics in the US and Canada were included in the analysis. Evaluation included reliability of scores, internal structure of the survey, evidence of convergent and divergent validity, and test–retest reliability.

Results

One hundred and ten patients with LS (age: 8–20 years) completed the LoSQI. Both exploratory and confirmatory factor analysis supported the use of two sub‐scores: Pain and Physical Functioning, and Body Image and Social Support. Correlations with other PRO measures were consistent with pre‐specified hypotheses.

Limitations

This study did not evaluate longitudinal validity or responsiveness of scores.

Conclusion

Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeScleroderma, LocalizedAdolescentHumansChildYoung AdultAdultReproducibility of ResultsCross-Sectional StudiesPatient Reported Outcome MeasuresPsychometricsSurveys and Questionnaires

Autor:innen und Institutionen

  • Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
  • Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas, USA.
  • School of Education, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA.

ORCID-Profile: C K Zigler

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Zigler, C. K., Lin, L., Ardalan, K., Jacobe, H., Lane, S., Li, S. C., Luca, N. J. C., Prajapati, V. H., Schollaert, K., Teske, N., & Torok, K. (2023). Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19059

Vancouver

Zigler CK, Lin L, Ardalan K, Jacobe H, Lane S, Li SC, et al. Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19059

BibTeX
@article{Zigler2023,
  author = {Zigler, C K and Lin, L and Ardalan, K and Jacobe, H and Lane, S and Li, S C and Luca, N J C and Prajapati, V H and Schollaert, K and Teske, N and Torok, K},
  title = {Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19059}
}
Kostenlos starten →